SUMMARY To determine the optimum dose of ispaghula husk in patients with irritable bowel syndrome (IBS) and to assess the correlation, if any between the relief in patients' symptoms and the whole gut transit time, and the increase in stool weight, a two part study was carried out. In part 1, 14 male patients were given ispaghula husk in increasing doses of 10 g, 20 g, and 30 g a day for a duration of 17 days each (14 days of study period+three days of stool collection). Ten patients completed the trial. The symptom score improved significantly with all the three doses of ispaghula. Both 20 g and 30 g doses of ispaghula were superior to the 10 g dose but there was no significant difference between the 20 g and 30 g doses. There was a significant (p<0.001) increase in the daily stool weight with 10 g dose of fibre with further significant increases with the 20 g and 30 g doses. A positive correlation was seen between the improvement in the symptom score and the increase in stool weight with the 10 g dose of ispaghula but not with the 20 g and 30 g doses. Whole gut transit time remained fairly constant throughout the study period and there was no relationship with either the dose of ispaghula, the alteration in stool weight, or the improvement in the patients symptoms. Ten patients completed part 2 of the study in which ispaghula husk was given in the same dose (10 g, 20 g, and 30 g) but in a random order and with a 'washout' period of one week between individual doses. Again all the three doses of ispaghula produced a significant improvement in the symptoms; 20 g and 30 g doses were equally effective and both were significantly superior to the 10 g dose. Assessed individually, all the three symptoms improved significantly; improvement in constipation and pain abdomen was more pronounced than diarrhoea. It is concluded that the optimum dose of ispaghula husk in irritable bowl syndrome is 20 g per day. There is some correlation between the increase in stool weight and the improvement in symptom score but the whole gut transit time remains unchanged despite alterations in stool weight and patients' symptoms.
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Some studies'5 but not others67 show that administra-other drugs.34 A number of aspects of the therapeutic tion of fibre, results in significant improvement in the role of fibre in irritable bowel syndrome remain to be symptoms of patients with irritable bowel syndrome. established, however, for example, the optimum This beneficial effect has been noted not only in the dose of fibre in irritable bowel syndrome has not west but also in India24 where the diet is compara-been determined. Moreover, the effect of different tively richer in its fibre content.8 Furthermore, fibre is quantities of fibre on the stool weight and the whole useful whether it is used alone or in combination with gut transit time, and the relationship of these parameters with the clinical response of the patient 
Stool weight
The mean daily stool weight was calculated from the total stool passed during 72 h, starting immediately after ingestion of the markers.`À ssessment of the clinical response to treatment was made 14 days after starting a particular dose of ispaghula husk. Stool collection for assessment of transit time and stool weight was started from day 15 to day 17, while the patient was still on the same dose of fibre. PART 2 Nineteen consecutive male patients were included inf9 this part of the study. The criteria of selection and the method of clinical assessment were the same as in part 1. Transit time and stool weight studies were not carried out, however. Each patient received all three doses (10 g, 20 g, and 30 g/day) of ispaghula husk; the order of administration was randomised according to a pre-arranged table. Treatment was continued for two weeks with a 'wash out' period of one week between individual doses. Clinical assessment was made at the end of each two weeks of study period. The person assessing the clinical status was not informed about the dose of fibre received by the patient.
STATISTICAL ANALYSIS Paired Student's t test was applied for comparing stool weight and transit time values with various doses of isphagula husk. The t test value was first validated by carrying out the one-way analysis of variance. Changes in the individual symptom scores with different doses of fibre were compared using the Wilcoxon's signed rank sum test. Because of the skewed distribution of the values of stool weight in the original units, log values were used while assessing the increase in stool weight.
Results

PART 1
Clinical assessment Ten of the 14 patients completed the study. The mean (±SD) age of the 10 patients was 32-6 (±20.4) years The most common symptom (nine of 10 patients) was incomplete evacuation of the bowel (Fig. 1 ). This symptom was present irrespective of whether the patient complained of diarrhoea or constipation. The next commonest symptom was constipation (eight) followed by abdominal pain (five), diarrhoea (five), passage of mucus in stools (four) and abdominal distension (three); the overlap of figures is because a number of patients had more than one symptom. Six patients noted a close relationship between the bowel complaints and emotional stress.
After treatment with 10 g ispaghula husk for two weeks, there was a significant improvement (p<001) in the symptom score (mean±SD=4*5±2.8) (Fig. 2) . When the amount of fibre was increased to 20 g a day the sympton score showed a further improvement (mean±SD=8*9±3.1) and the difference from the 10 g dose was highly significant (p<0-001). A further increase in the amount of fibre to 30 g a day resulted in only a marginal improvement (mean±SD= 9.45±2*1) over the 20 g dose, the difference being not significant. All four patients who dropped out of the study did so while on the 30 g dose and complained of difficulty in consuming such large quantities of fibre. There were no fibre-related unwanted effects and all patients who completed the trial tolerated it well.
Stool weight
The pretreatment stool weight showed marked variations in different patients (range 90 g-493 g). After administration of ispaghula husk there was a significant (p<0-001) increase in the stool weight over the base line value (Table) . Again there was a wide variation in the increase in stool weight in different patients (range 30 g-325 g). With 20 g ispaghula the (Fig.  2) . After two weeks of treatment, the mean (±SD) total symptom scores were: 4-8 (±4-4) with 10 g dose of fibre, 7-15 (±3.72) with 20 g and 6*4 (±4.25) with 30 g. All three doses produced a statistically significant (p<0-01 for 10 g and 30 g; p<0-001 for 20 g) improvement in the symptom score. Again, the 20 g and 30 g doses of ispaghula were superior (p<0-05 for each) to the 10 g dose while there was no significant difference between 20 g and 30 g doses. None of the patients in this group complained of any fibre related unwanted effects.
Effect of ispaghula husk on individual symptoms
The effect of ispaghula on individual symptoms was also assessed. For this purpose, the results of part 1 and 2 were combined so as to obtain a sufficient number of subjects in each group. The results are shown in Fig. 4 . All the three doses of fibre produced a significant improvement (p<0-001 for each dose) in constipation. Both 20 g and 30 g doses were superior to the 10 g dose (p<0.001 and <0-01 respectively) but there was no difference between the two larger doses. Similar results were obtained in the relief of abdominal pain. Improvement in diarrhoea was also statistically significant with each dose of ispaghula but the response was less pronounced compared with the other two symptoms; 20 g was superior to the 10 g dose of fibre but there was no difference between 10 g and 30 g doses.
Discussion
In part 1 of the study ispaghula husk was administered successfully in gradually increasing quantities of 10 g, 20 g, and 30 g with no 'wash out' period between the doses. Such a protocol had the theoretical disadvantage that the effect of one dose of fibre could 'spill over' to the next dose and thus influence the final result. To obviate this, in part 2, the three doses of ispaghula were given in a random order and in a blind fashion with a 'wash out' period of one week between two doses. Only male patients were included in the study because it has been observed that women show alterations in the bowel habit during the course of a menstrual cycle." The beneficial effect of placebo in irritable bowel syndrome has been well described.67 We did not include a placebo control group, however, for various reasons: (a) it is difficult to devise an 'inert' material which can be made to resemble ispaghula husk, (b) fibre can be given in capsules but it would require approximately 90 capsules a day to administer a dose of 30 g, (c) another method of disguising fibre is to administer it as biscuits but this requires cooking and defeats the purpose of testing a material in a ('natural') form in which it is normally going to be consumed and (d) moreover, the main purpose of the present study was to determine the optimum dose We had a high drop out rate of 39% (13 out of 33). Most of these patients (8; 61-5%) dropped out while on the 30 g dose because they found it difficult to consume such large quantities of fibre. The remaining five (two on 10 g and three on 20 g) dropped out because they felt sufficiently well and did not wish to carry on with the study.
It is concluded that the optimum dose of ispaghula husk in the treatment of irritable bowel syndrome is 20 g per day. The mechanism by which dietary fibre improves the patients symptoms is related to some extent to the increase in the stool weight but is independent of the whole gut transit time of food. 
